Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01126450 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01126450: Clinical Trial Phase 1 study, sponsored by Case Comprehensive Cancer Center.
NCT01126450 is a Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01126450, a Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving lenalidomide together with cetuximab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with cetuximab in treating patients with metastatic colorectal cancer.
Interventions
- DRUG lenalidomide
- BIOLOGICAL cetuximab
- GENETIC polymorphism analysis
- OTHER polymerase chain reaction
- OTHER mutation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Why NCT01126450 stopped before completion
NCT01126450 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which lenalidomide is the first listed.
NCT01126450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01126450 about?
NCT01126450 is a clinical study titled "Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-kill...
What is the current status of trial NCT01126450?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2009-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01126450?
The interventions under investigation include: lenalidomide (DRUG), cetuximab (BIOLOGICAL), polymorphism analysis (GENETIC), polymerase chain reaction (OTHER), mutation analysis (OTHER).
Who is sponsoring clinical trial NCT01126450?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01126450's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia